Lexicon Pharmaceuticals, Inc.
LXRX· Nasdaq
LXRXLexicon Pharmaceuticals, Inc.
Filed Mar 12, 2020 · 10-K · 72 days after period end · 0001062822-20-000015
| Metric | Q4 2019 | Q4 2016dderived from reported figures | Q4 2015 | Q4 2014 |
|---|---|---|---|---|
| Revenue | $8.73M | -$41.83M | $23.04M | $127.28M |
| Net Income | -$51.14M | -$28.38M | -$32.42M | $86.75M |
| EPS Diluted | -$0.48 | — | -$0.31 | $0.76 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lexicon Pharmaceuticals, Inc. · CIK 1062822 · Engraved from SEC EDGAR
ended Dec 31, 2019 · filed Mar 12, 2020 · 72 d after period end
